ATE550338T1 - Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit - Google Patents

Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit

Info

Publication number
ATE550338T1
ATE550338T1 AT06787495T AT06787495T ATE550338T1 AT E550338 T1 ATE550338 T1 AT E550338T1 AT 06787495 T AT06787495 T AT 06787495T AT 06787495 T AT06787495 T AT 06787495T AT E550338 T1 ATE550338 T1 AT E550338T1
Authority
AT
Austria
Prior art keywords
spiropiperidine
secretase
alzheimer
inhibitors
beta
Prior art date
Application number
AT06787495T
Other languages
English (en)
Inventor
Craig Coburn
Melissa Egbertson
Samuel Graham
Georgia Mcgaughey
Shaun Stauffer
Hemaka Rajapakse
Philippe Nantermet
Shawn Stachel
Wenjin Yang
Wanli Lu
Bruce Fahr
Original Assignee
Merck Sharp & Dohme
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Sunesis Pharmaceuticals Inc filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE550338T1 publication Critical patent/ATE550338T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AT06787495T 2005-07-18 2006-07-14 Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit ATE550338T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70009005P 2005-07-18 2005-07-18
PCT/US2006/027594 WO2007011833A2 (en) 2005-07-18 2006-07-14 Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
ATE550338T1 true ATE550338T1 (de) 2012-04-15

Family

ID=37491690

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06787495T ATE550338T1 (de) 2005-07-18 2006-07-14 Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit

Country Status (12)

Country Link
US (1) US8211904B2 (de)
EP (1) EP1910364B1 (de)
JP (1) JP2009502786A (de)
CN (1) CN101238124A (de)
AR (1) AR054560A1 (de)
AT (1) ATE550338T1 (de)
AU (1) AU2006270084B2 (de)
CA (1) CA2615656A1 (de)
DO (1) DOP2006000169A (de)
PE (1) PE20070367A1 (de)
TW (1) TW200728305A (de)
WO (2) WO2007011810A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004069182A2 (en) * 2003-02-01 2004-08-19 Neuralab Limited Active immunization to generate antibodies to soluble a-beta
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2006066089A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
US7759353B2 (en) 2005-06-14 2010-07-20 Schering Corporation Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods of treatment
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
WO2008030412A2 (en) * 2006-09-07 2008-03-13 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008045250A1 (en) * 2006-10-06 2008-04-17 Merck & Co., Inc. Macrocyclic spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
AU2007314338A1 (en) 2006-10-30 2008-05-08 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease
EP2117309B1 (de) * 2007-01-04 2013-11-06 Merck Sharp & Dohme Corp. Bizyklische spiropiperidin-beta-sekretase-hemmer zur behandlung der alzheimer-krankheit
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
BRPI0810118A8 (pt) * 2007-04-18 2015-09-29 Janssen Alzheimer Immunotherap Método para tratar doença, método para efetuar profilaxia contra caa, uso de um agente, método para reduzir amilóide vascular em um paciente, e, kit para tratamento
TW200902499A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
PL2182983T3 (pl) 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CA2711655C (en) 2008-01-18 2013-03-05 Eisai R&D Management Co., Ltd. Condensed aminodihydrothiazine derivative
EP2300484B1 (de) * 2008-05-05 2011-12-14 Pfizer Inc. Neue klasse von spiro-piperidinen zur behandlung neurodegenerativer krankheiten
US8501733B2 (en) 2008-07-28 2013-08-06 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
JP5444240B2 (ja) * 2008-07-28 2014-03-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
CA2736130C (en) 2008-09-11 2014-01-14 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
KR20110076965A (ko) 2008-09-30 2011-07-06 에자이 알앤드디 매니지먼트 가부시키가이샤 신규한 축합 아미노 디하이드로티아진 유도체
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
CA2743584A1 (en) * 2008-11-23 2010-05-27 Pfizer Inc. Lactams as beta secretase inhibitors
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
EP2281824A1 (de) 2009-08-07 2011-02-09 Noscira, S.A. Furan-Imidazolon-Derivate zur Behandlung von kognitiven, neurodegenerativen oder neuronalen Erkrankungen oder Funktionsstörungen
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US8883782B2 (en) 2010-03-15 2014-11-11 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
US8497264B2 (en) 2010-03-15 2013-07-30 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
CA2795877A1 (en) 2010-04-09 2011-10-13 Pfizer Inc. Novel sultam compounds
US8921363B2 (en) 2010-08-05 2014-12-30 Amgen Inc. Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors
WO2012069428A1 (en) 2010-11-22 2012-05-31 Noscira, S.A. Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
EP2643325A1 (de) 2010-11-23 2013-10-02 Amgen Inc. Spiro-amino-imidazolon- und spiro-amino-dihydro-pyrimidinonverbindungen als beta-sekretase-modulatoren und verwendungsverfahren dafür
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
BR112013016241A2 (pt) 2011-01-21 2016-07-12 Eisai R&D Man Co Ltd composto, e, método para fabricar um composto
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
US8962859B2 (en) 2011-02-15 2015-02-24 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2012138590A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US9079919B2 (en) * 2011-05-27 2015-07-14 Hoffmann-La Roche Inc. Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors
BR112014004181A2 (pt) 2011-08-22 2017-06-13 Merck Sharp & Dohme composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US9403802B2 (en) 2012-03-02 2016-08-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use therefor
US9725469B2 (en) 2012-11-15 2017-08-08 Amgen, Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US8742111B1 (en) * 2013-02-21 2014-06-03 The United States Of America As Represented By The Secretary Of The Army Synthesis of intermediate anilino methyl esters used in the production of synthetic opioid analgesics
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
EP3233799B1 (de) 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamin-d2-rezeptor-liganden
WO2016139501A1 (en) * 2015-03-04 2016-09-09 Tfchem Gem difluorocompounds as depigmenting or lightening agents
EP3461819B1 (de) 2017-09-29 2020-05-27 Probiodrug AG Hemmer der glutaminylcyclase
CA3163243A1 (en) * 2019-12-03 2021-06-10 Kallyope, Inc. Sstr5 antagonists

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710504A (en) * 1986-04-04 1987-12-01 Merck & Co., Inc. Anti-depressant spiro hexahydro arylquinolizine derivatives, composition, and method of use therefor
US5221675A (en) * 1989-12-15 1993-06-22 Abbott Laboratories Aza-spirocyclic compounds that enhance cholinergic neurotransmission
US5534520A (en) * 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
AU2494792A (en) * 1991-08-19 1993-03-16 E.I. Du Pont De Nemours And Company Angiotensin ii receptor blocking imidazolinone derivatives
FR2725206B1 (fr) * 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
WO1999065494A1 (en) 1998-06-15 1999-12-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US20040067950A1 (en) * 1998-07-27 2004-04-08 Schering-Plough Corporation High affinity ligands for nociceptin receptor ORL-1
EP1461339B1 (de) 2001-12-28 2010-04-28 Acadia Pharmaceuticals Inc. Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
AU2003223093B2 (en) * 2002-05-03 2010-02-04 Israel Institute For Biological Research Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
EP1515944A1 (de) 2002-06-17 2005-03-23 Sunesis Pharmaceuticals, Inc. Aspartyl-protease inhibitoren
JP2006512404A (ja) 2002-10-22 2006-04-13 グラクソ　グループ　リミテッド Ｈ３受容体リガンドとしてのアリールオキシアルキルアミン誘導体
AU2003298889A1 (en) 2002-12-04 2004-06-23 Merck & Co., Inc. Spirocyclic ureas, compositions containing such compounds and methods of use
WO2004055016A1 (en) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Pyrrolidine and azetidine compounds as ccr5 antagonists
AU2003297826A1 (en) 2003-06-16 2005-01-28 Sunesis Pharmaceuticals, Inc Aspartyl protease inhibitors
GB0323204D0 (en) * 2003-10-03 2003-11-05 Novartis Ag Organic compounds
EP1804794B1 (de) * 2004-10-13 2013-07-31 Merck Sharp & Dohme Corp. Spiropiperidin-verbindungen als beta-secretase-hemmer zur behandlung der alzheimer-krankheit

Also Published As

Publication number Publication date
EP1910364B1 (de) 2012-03-21
AU2006270084B2 (en) 2011-08-25
EP1910364A2 (de) 2008-04-16
US20070021454A1 (en) 2007-01-25
DOP2006000169A (es) 2007-02-28
AU2006270084A1 (en) 2007-01-25
CN101238124A (zh) 2008-08-06
WO2007011833A2 (en) 2007-01-25
WO2007011833A3 (en) 2007-03-29
CA2615656A1 (en) 2007-01-25
AR054560A1 (es) 2007-06-27
TW200728305A (en) 2007-08-01
JP2009502786A (ja) 2009-01-29
PE20070367A1 (es) 2007-05-12
US8211904B2 (en) 2012-07-03
WO2007011810A1 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
DE602006019560D1 (de) 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
EP1643986A4 (de) Phenylcarboxylat-beta-secretase-hemmer zur behandlung von morbus alzheimer
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
EP2063889A4 (de) Spiropiperidin-beta-sekretase-hemmer zur behandlung der alzheimer-krankheit
DE602005017503D1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE524479T1 (de) Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
EP1641748A4 (de) N-alkylphenylcarboxamid-beta-secretase-hemmer zur behandlung von alzheimer-krankheit
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
EP1758854A4 (de) Als beta-sekretase-inhibitoren für die behandlung von alzheimer-krankheit geeignete pyrrolidin-3-yl-verbindungen
EP1807396A4 (de) 2-aminopyridinzusammensetzungen als beta-sekretase-hemmer zur behandlung von morbus alzheimer
ATE504580T1 (de) Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit
EP1855679A4 (de) Aminomethyl-beta-sekretase-hemmer zur behandlung von alzheimer
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit